Detalles de la búsqueda
1.
Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.
Proc Natl Acad Sci U S A
; 121(17): e2321898121, 2024 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38625939
2.
Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas.
Gynecol Oncol
; 187: 12-20, 2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38703673
3.
Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.
Gynecol Oncol
; 2024 Feb 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38493021
4.
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
Ann Surg Oncol
; 30(9): 5597-5609, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37358686
5.
Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.
Gynecol Oncol
; 168: 157-165, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36442427
6.
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.
Gynecol Oncol
; 170: 38-45, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36610380
7.
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
Gynecol Oncol
; 170: 172-178, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36706643
8.
Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor.
Gynecol Oncol
; 169: 98-105, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36525930
9.
Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.
Gynecol Oncol
; 172: 65-71, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36958197
10.
Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers.
Int J Mol Sci
; 24(10)2023 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37240216
11.
Antibody-Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors.
Molecules
; 28(21)2023 Nov 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37959808
12.
Laparoscopic pancreatic peritonectomy with splenectomy for recurrent ovarian cancer: a novel approach to achieve R0 while preserving the pancreatic body and tail.
Int J Gynecol Cancer
; 2024 May 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38724238
13.
Corrigendum to "Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma".
Gynecol Oncol
; 170: 334, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36906375
14.
"I'm used to doing it by myself": exploring self-reliance in pregnancy.
BMC Pregnancy Childbirth
; 18(1): 393, 2018 Oct 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30290785
15.
Increasing hepatitis C prevalence and associated risk behaviors among incarcerated young adults.
J Urban Health
; 91(2): 376-82, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23722268
16.
Gynecologic Care for Sexual and Gender Minority Patients.
Obstet Gynecol Clin North Am
; 51(1): 17-41, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38267126
17.
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147).
Clin Cancer Res
; 30(9): 1768-1777, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38592381
18.
Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals.
Int J Womens Health
; 15: 1353-1365, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37663226
19.
Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer.
Expert Opin Biol Ther
; 23(3): 227-233, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36800548
20.
HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma.
Cancers (Basel)
; 15(16)2023 Aug 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37627113